The recent crisis at Sarepta Therapeutics, marked by the tragic deaths of three patients in its gene therapy programs, has rapidly become a defining moment for the biotechnology sector.
Unfolding of the Crisis: A Timeline of Consequences
Patient Deaths: Three fatalities, all linked to Sarepta’s gene therapy products utilizing AAV vectors—two teenagers after Elevidys treatment for Duchenne muscular dystrophy and a 51-year-old in an investigational trial.
Regulatory Confrontation: The FDA’s prompt request for the voluntary halt of Elevidys shipments was rebuffed by Sarepta, escalating tensions to an unprecedented level between the company and its regulator.
Disclosure Failure: Sarepta failed to disclose the third death to investors during a significant restructuring announcement, despite having prior knowledge. When questioned, CEO Doug Ingram rationalized the omission as “neither material nor relevant,” which triggered widespread backlash.
